The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes

GLIA

Volumn 62, Issue 5, 2014, Pages 725-735

  Elain, Gaelle ^a   Jeanneau, Karine ^a   Rutkowska, Aleksandra ^b   Mir, Anis K ^a   Dev, Kumlesh K ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Multiple sclerosis (MS); NF B pathway; Tumor necrosis factor (TNF )

Indexed keywords

CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17A RECEPTOR; INTERLEUKIN 17C RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; RECEPTOR SUBTYPE; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL17A PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; BIOLOGICAL ACTIVITY; BRAIN CORTEX; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FLUORESCENCE; GESTATIONAL AGE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; METABOLISM; NEWBORN;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; ASTROCYTES; CELLS, CULTURED; CEREBRAL CORTEX; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL;

EID: 84896314616     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22637     Document Type: Article

References (49)

1. Baeten D, Sieper J, Emery P, Braun J, van der Heijde D, McInnes I, van Laar J, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Bertolino A, Wright A, Hueber W. 2010. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum 62:2840-2841.
2. Bogoljub C, Abdolmohamad R. 2010. IL-17A in autoimmune inflammation of the central nervous system: A promising therapeutic target in multiple sclerosis? Open Autoimmun J 2:171-180.
3. Das Sarma J, Ciric B, Marek R, Sadhukhan S, Caruso ML, Shafagh J, Fitzgerald DC, Shindler KS, Rostami A. 2009. Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflammation 28:6-14.
4. Damjanov N, Kauffman RS, Spencer-Green GT. 2009. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60:1232-1241.
5. Deiß A, Brecht I, Haarmann A, Buttmann M. 2013. Treating multiple sclerosis with monoclonal antibodies: A 2013 update. Expert Rev Neurother 13:313-335.
6. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Liew SH, Bezlyak V, Androudi S. 2013. Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials. Ophthalmology 120:777-787.
7. Dong Y, Benveniste EN. 2001. Immune function of astrocytes. Glia 36:180-190.
8. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. 2009. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 65:499-509.
9. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. 1989. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 19:689-694.
10. Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, Orthey E, Arumugam TV, Leypoldt F, Simova O, Thom V, Friese MA, Prinz I, Hölscher C, Glatzel M, Korn T, Gerloff C, Tolosa E, Magnus T. 2012. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood 120:3793-3802.
11. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S. 2012. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72:863-869.
12. Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C, Kaplin AI, Nath A, Kerr DA, Calabresi PA. 2008. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol 196:124-132.
13. Gruol DL, Nelson TE. 1997. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15:307-339.
14. Haroon F, Drögemüller K, Händel U, Brunn A, Reinhold D, Nishanth G, Mueller W, Trautwein C, Ernst M, Deckert M, Schlüter D. 2011. Gp130-dependent astrocytic survival is critical for the control of autoimmune central nervous system inflammation. J Immunol 186:6521-6531.
15. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R. 2005. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 237:123-130.
16. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:72.
17. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group. 2012. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693-1700.
18. Huppert J, Closhen D, Croxford A, White R, Kulig P, Pietrowski E, Bechmann I, Becher B, Luhmann HJ, Waisman A, Kuhlmann CR. 2010. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J 24:1023-1034.
19. Jiang G, Ke Y, Sun D, Wang Y, Kaplan HJ, Shao H. 2009. Regulatory role of TLR ligands on the activation of autoreactive T cells by retinal astrocytes. Invest Ophthalmol Vis Sci 50:4769-4776.
20. Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W, Ransohoff RM, Bergmann C, Stohlman S, Tuohy VK, Li X. 2010. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signalling ameliorates autoimmune encephalomyelitis. Immunity 32:414-425.
21. Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H, Suzumura A. 2008. Production and functions of IL-17 in microglia. J Neuroimmunol 194:54-61.
22. Ke Y, Jiang G, Sun D, Kaplan HJ, Shao H. 2009. Retinal Astrocytes respond to IL-17 differently than Retinal Pigment Epithelial cells. J Leukoc Biol 86:1377-1384.
23. Kimura A, Kishimoto T. 2010. IL-6: Regulator of Treg/Th17 balance. Eur J Immunol 40:1830-1835.
24. Koch M, May U, Kuhns S, Drechsler H, Adam N, Hattermann K, Wirtz S, Rose-John S, Scheller J. 2007. Interleukin 27 induces differentiation of neural C6-precursor cells into astrocytes. Biochem Biophys Res Commun 364:483-487.
25. Liu JQ, Carl JW Jr, Joshi PS, RayChaudhury A, Pu XA, Shi FD, Bai XF. 2007. CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J Immunol 178:6227-6235.
26. Nichols JR, Aldrich AL, Mariani MM, Vidlak D, Esen N, Kielian T. 2009. TLR2 deficiency leads to increased Th17 infiltrates in experimental brain abscesses. J Immunol 182:7119-7130.
27. Ma X, Reynolds SL, Baker BJ, Li X, Benveniste EN, Qin H. 2010. IL-17 enhancement of the IL-6 signaling cascade in astrocytes. J Immunol 184:4898-4906.
28. Martins TB, Rose JW, Jaskowski TD, Wilson AR, Husebye D, Seraj HS, Hill HR. 2011. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol 136:696-704.
29. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. 1999. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5:101-104.
30. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP. 2014. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73:349-356.
31. Meares GP, Ma X, Qin H, Benveniste EN. 2012. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 60:771-781.
32. Meeuwsen S, Persoon-Deen C, Bsibsi M, Ravid R, van Noort JM. 2003. Cytokine, chemokine and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuli. Glia 43:243-253.
33. Miljkovic D, Momcilovic M, Stojanovic I, Stosic-Grujicic S, Ramic Z, Mostarica-Stojkovic M. Astrocytes stimulate interleukin-17 and interferon-gamma production in vitro. 2007. J Neurosci Res 85:3598-3606.
34. Miyamoto R, Ito T, Nomura S, Amakawa R, Amuro H, Katashiba Y, Ogata M, Murakami N, Shimamoto K, Yamazaki C, Hoshino K, Kaisho T, Fukuhara S. 2010. Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells. Arthritis Res Ther 12:R87.
35. Paintlia MK, Paintlia AS, Singh AK, Singh I. 2011. Synergistic activity of interleukin-17 and tumor necrosis factor-alpha enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem 116:508-521.
36. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. 2013. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168:412-421.
37. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133-1141.
38. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, Mellor GW, Evans C, Roshak AK. 2005. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 312:373-381.
39. Qin H, Benveniste EN. 2012. ELISA methodology to quantify astrocyte production of cytokines/chemokines in vitro. Methods Mol Biol 814:235-249.
40. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. 2013. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168:402-411.
41. Sharief MK, Hentges R. 1991. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472.
42. Shi N, Kawano Y, Matsuoka T, Mei F, Ishizu T, Ohyagi Y, Kira J. 2009. Increase of CD4+TNFα+IL2-T cells in cerebrospinal fluid of multiple sclerosis patients. Mult Scler 15:120-123.
43. Trajkovic V, Stosic-Grujicic S, Samardzic T, Markovic M, Miljkovic D, Ramic Z, Mostarica Stojkovic M. 2001. Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes. J Neuroimmunol 119:183-191.
44. Traugott U, Reinherz EL, Raine CS. 1983. Multiple sclerosis: Distribution of T cell subsets within active chronic lesions. Science 219:308-310.
45. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146-155.
46. Witowski J, Ksiazek K, Jorres A. 2004. Interleukin-17: A mediator of inflammatory responses. Cell Mol Life Sci 61:567-579.
47. Yan HQ, Banos MA, Herregodts P, Hooghe R, Hooghe-Peters EL. 1992. Expression of interleukin (IL)-1 beta, IL-6 and their respective receptors in the normal rat brain and after injury. Eur J Immunol 22:2963-2971.
48. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-511.
49. Zepp J, Wu L, Li X. 2011. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 32:232-239.